ARTICLE | Clinical News

Protectan CBLB502: Phase I started

December 7, 2009 8:00 AM UTC

Cleveland Biolabs began a U.S. Phase I trial in 100 healthy volunteers to evaluate a single injection of 25 or 35 µg CBLB502, a single dose of 400 mg ibuprofen followed by 35 µg CBLB502, or two 30 µg ...